Effect of Tolvaptan on hemodynamic of congestive heart failure.

Effect of Tolvaptan on hemodynamic of congestive heart failure. - Effect of Tolvaptan on hemodynamic of congestive heart failure.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012170

Enrollment

Registered

2013-10-31

Start date

2012-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Congestive heart failure

Interventions

Tolvaptan group Tolvaptan 7.5mg/day and Fulosemide 10mg/day are administered for 7days. If not effective, Tolvaptan is administered up to 15mg/day. Control group Fulosemide in administered for 7days

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients who diagnosed Congestive heart failure 2. NYHA class III or IV 3. Patients who are admitted to our hospital.

Exclusion criteria

Exclusion criteria: 1. Hypernatremia (serum sodium >= 146mEq/L) 2. Hyponatremia (serum sodium < 125mEq/L) 3. Hyperkalemia (serum potassium >= 5.1mEq/L) 4. Anuric patients 5. Renal insufficiency (serum creatinine > 4.0mEq/L 6. Systolic blood pressure < 90mmHg 7. Severe coronary artery disease or cerebrovascular disease 8. Hypertrophic obstructive cardiomyopathy or severe valvular heart disease 9. Patients who cannot declare thirst or cannot drink water 10. Expectant mother 11. Patients who implanted pace maker, ICD, CRT-D or mechanical valves 12. Intubation 13. Hypersensitivity for Tolvaptan or Mozavaptan 14. Inappropriate patients judged by the physician in charge

Design outcomes

Primary

Measure	Time frame
hemodynamic	—

Countries

Japan

Contacts

Public ContactKeishi Ishikawa

Chiba University Graduate School of Medicine Department of Cardiovascular Medicine

LapisLazurite@hotmail.com043-226-2340

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026